Offerings - Norwegian Air Shuttle ASA – Rights Issue
Arctic Securities is acting as Joint Bookrunner in relation to the Rights Issue in Norwegian Air Shuttle ASA
The Arctic Group is a leading, independent provider of financial services
The Arctic Group is a leading, independent provider of financial services
Arctic Securities is acting as Joint Bookrunner in relation to the Rights Issue in Norwegian Air Shuttle ASA
Our very own Ulrica Slåne Bjerke was today interviewed by EFN talking about a very positive January performance in the healthcare and biotech sector. In Børslunch, Ulrica talks about companies like Eli Lilly, Loxo, Gilead and Nordic Nanovector along with Mårten Steen from Healthcap.
Arctic Securities is acting as financial advisor in relation to the 90 percent secured rights issue of SEK 15.6m for the Swedish listed vaccine company Eurocine Vaccines AB (publ). Eurocine Vaccines AB (publ) is referred to as “Eurocine Vaccines” or “the Company”. Shareholders have pre-emptive rights to subscribe for shares. Three (3) existing shares held on the record date of March 21, 2019, entitles to five (5) new shares. Subscription price of SEK 0.11 per share. The subscription period runs 25 March – 8 April, 2019. The rights issue is secured up to 90 percent through subscription- and guarantee undertakings. A Swedish memorandum and subscription note will be available before the subscription period on Eurocine Vaccines website, www.eurocine-vaccines.com and Arctic Securities website.
Arctic Securities acted as Joint Bookrunner in relation to the Private Placement of NOK 230 million in Vaccibody AS.